Home › Opioid Overdose › Illinois › Chicago
Opioid Overdose clinical trials in Chicago, IL
5 studies for Opioid Overdose are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study of Brenipatide in Participants With Opioid Use Disorder
RecruitingPhase 2
- Re:Cognition Health - Chicago, Chicago
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
RecruitingPhase 2
- Ruth M. Rothstein CORE Center, Chicago
Implementing Contingency Management for Stimulant Use in Specialty Addiction Treatment Organizations
Recruiting
- ACCESS Community Health Networks, Chicago
- Community Outreach Intervention Projects, Chicago
- Family Guidance Centers, Chicago
Remotely Observed Methadone Evaluation II
RecruitingPhase 2
- FGC Wabash, Chicago
EEG Biomarkers for OUD: Diagnostic, Prognostic, and Predictive Applications
RecruitingObservational studyHealthy volunteers welcome
- Clinical & Imaging Research Outcomes Lab, Chicago
About Opioid Overdose
Opioid overdose leads to slowing or stopping of breathing and sometimes death. You can take steps to help prevent an overdose, and respond to one with naloxone.
More about Opioid Overdose on MedlinePlus
Opioid Overdose trials in other cities
- Baltimore, MD18 studies
- New Haven, CT17 studies
- Philadelphia, PA15 studies
- Boston, MA12 studies
- New York City, NY12 studies
- Salt Lake City, UT8 studies
- Pittsburgh, PA7 studies
- Birmingham, AL6 studies
- Providence, RI6 studies
- Ann Arbor, MI6 studies
- Charleston, SC6 studies
- San Francisco, CA6 studies
Other studies in Chicago
- Non-Small Cell Lung Cancer62 studies
- Breast Cancer58 studies
- Cancer (all types)53 studies
- Metastatic Cancer45 studies
- Prostate Cancer45 studies
- Obesity42 studies
- Lung Cancer41 studies
- Ovarian Cancer36 studies
- Stroke35 studies
- Heart Failure32 studies
- Colorectal Cancer32 studies
- Overweight28 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.